Mainz Biomed N.V — Balance Sheet (NASDAQ:MYNZ) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Total assets 10.04 M20.24 M15.41 M13.24 M Total liabilities 3.68 M6.14 M12.16 M7.19 M Total equity 6.36 M14.1 M3.25 M6.05 M Total liabilities & shareholders' equities 10.04 M20.24 M15.41 M13.24 M Total debt ———— Net debt ————

新闻

Mainz Biomed secures $6 million funding, shifts focus to pancreatic cancer

Mainz Biomed通过场内股票发行筹集215万美元

Mainz Biomed raises $2.15 million through at-the-market share offering

Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland - Mainz Biomed (NASDAQ:MYNZ)

Mainz Biomed’s colorectal cancer test receives Swiss regulatory approval

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Affimed (NASDAQ:AFMD), Abpro Hldgs (NASDAQ:ABP)

Mainz Biomed to update on CRC screening study by end of summer

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024 - Quest Diagnostics (NYSE:DGX), Mainz Biomed (NASDAQ:MYNZ)

Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Mainz Biomed (NASDAQ:MYNZ)